Get the Stockscreener App
103.32
2.47%
2.45
Illumina Inc stock is traded at $103.32, with a volume of 589.23K.
It is up +2.47% in the last 24 hours and up +2.82% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$100.87
Open:
$102.31
24h Volume:
589.23K
Relative Volume:
0.31
Market Cap:
$15.87B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
13.08
EPS:
7.9
Net Cash Flow:
$943.00M
1W Performance:
+4.08%
1M Performance:
+2.82%
6M Performance:
+21.38%
1Y Performance:
-21.08%
1-Day Range:
$101.60
$103.78
1-Week Range:
$95.12
$104.22
52-Week Range:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
103.28 | 15.50B | 4.28B | 1.26B | 943.00M | 7.90 |
|
TMO
Thermo Fisher Scientific Inc
|
480.45 | 178.47B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
195.21 | 138.15B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
656.15 | 51.27B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
128.07 | 35.93B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
189.37 | 31.74B | 15.70B | 1.24B | 2.01B | 6.91 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Video: Illumina staff share who inspired them to work in genomics - Illumina
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - Illumina
250,000 Genome Database Gets Major Boost: Alnylam Joins Elite Pharma Alliance for Breakthrough Drug Discovery - Stock Titan
US NGS Market Forecast and Company Analysis Report 2025-2033: Illumina, Thermo Fisher Scientific, Pacific Biosciences, QIAGEN, Roche, Bio-Rad Laboratories, Takara Bio, Hamilton, Geneious, BioMerieux - Yahoo Finance
Bioinformatics Market Evolution by 2032Disruptive Innovations, Regional Insights, and Growth Opportunities | Active Motif, Inc., Illumina, Inc. - industrytoday.co.uk
Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges - Markets Mojo
Gainers Report: What’s next for Illumina Inc. stock2025 Trade Ideas & Low Risk High Win Rate Picks - خودرو بانک
Fueling breakthrough research at Pedal the Cause - Illumina
Why Illumina Inc. (ILMN) Crashed Last Week - MSN
Long-Read Sequencing Technology | For challenging genomes - Illumina
Illumina aims to triple India business in five to seven years - MSN
United States miRNA Tools and Services Market Expansion Fueled - openPR.com
Clinical Genomics Market Opportunity Analysis and Industry - openPR.com
Returns Recap: Will Illumina Inc. announce a stock split2025 Price Action Summary & Capital Protection Trade Alerts - خودرو بانک
Epigenetics Market Outlook (2025–2032) : Strategic Growth Insights, Revenue Trends and Innovation Amidst Leaders Like Illumina Inc., Thermo Fisher Scientific Inc. - industrytoday.co.uk
Aug Gainers: Can Illumina Inc stock outperform in a bear marketQuarterly Performance Summary & Reliable Entry Point Trade Alerts - خودرو بانک
Loss Report: Can Illumina Inc stock outperform in a bear market2025 Market WrapUp & Long Hold Capital Preservation Plans - خودرو بانک
How an Illumina bioinformatics engineer contributes to the company mission - Illumina
Buy Signal: Is Illumina Inc. a strong growth stockMarket Sentiment Summary & Fast Entry Momentum Trade Alerts - خودرو بانک
EV Market: How does Illumina Inc. score in quality rankings2025 Key Highlights & Growth Focused Entry Reports - خودرو بانک
Precision Genomic Testing Market May See a Big Move | Major Giants- Illumina, BGI Genomics, Agilent Technologies - openPR.com
Alliancebernstein L.P. Sells 1,385,581 Shares of Illumina, Inc. $ILMN - MarketBeat
Plato Investment Management Ltd Sells 2,855 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Acquired by Bayforest Capital Ltd - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $4.77 Million Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Petrus Trust Company LTA Increases Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Royal Bank of Canada Increases Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Amundi Sells 255,844 Shares of Illumina, Inc. $ILMN - MarketBeat
Why Illumina (ILMN) Stock Is Falling Today - FinancialContent
eBook: Proteomics and Integral Proteomics Insights - News-Medical
Focus Partners Advisor Solutions LLC Takes Position in Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Sold by Ion Asset Management Ltd. - MarketBeat
Astrana Health, Privia Health, Illumina, Waters Corporation, and LeMaitre Shares Plummet, What You Need To Know - Yahoo Finance
Jacobs Levy Equity Management Inc. Acquires 1,152,048 Shares of Illumina, Inc. $ILMN - MarketBeat
Europe Non-Invasive Prenatal Testing Market Growth and Company Analysis Report 2025-2033 Featuring Eurofins Scientific, F. Hoffmann-La Roche, Invitae, Illumina, Natera, Centogene, and Qiagen - Yahoo Finance
Genomic Cancer Testing Market Outlook (2025-2032) : Strategic - openPR.com
Corvex Management LP Has $303.84 Million Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Unpleasant Surprises Could Be In Store For Illumina, Inc.'s (NASDAQ:ILMN) Shares - 富途牛牛
ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay - Yahoo Finance
Illumina Launches Tool Capable of Measuring 9,500 Human Protein Targets to Support Drug Discovery - geneonline.com
Illumina (ILMN): Buy, Sell, or Hold Post Q2 Earnings? - FinancialContent
Illumina Launches Protein Prep Tool Capable of Measuring 9,500 Human Protein Targets - geneonline.com
Maverick Capital Ltd. Raises Stake in Illumina, Inc. $ILMN - MarketBeat
Illumina Launches Tool to Measure 9,500 Human Protein Targets for Proteomic Research - geneonline.com
Real time social sentiment graph for Illumina Inc2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Southpoint Capital Advisors LP Purchases Shares of 500,000 Illumina, Inc. $ILMN - MarketBeat
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Illumina Inc Stock (ILMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thaysen Jacob | Chief Executive Officer |
May 12 '25 |
Buy |
80.88 |
6,500 |
525,732 |
77,540 |
| Thaysen Jacob | Chief Executive Officer |
May 13 '25 |
Buy |
80.84 |
5,850 |
472,942 |
83,390 |
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):